ADCT - Early-stage study commences on ADC antibody-drug conjugate in solid tumors

The first participant has been dosed in an additional arm of a Phase 1b clinical trial evaluating ADC Therapeutics' (ADCT) antibody-drug conjugate camidanlumab tesirine (Cami) (formerly ADCT-301), combined with Merck's (MRK) Keytruda (pembrolizumab), in patients with advanced solid tumors.The 95-subject, open-label, dose-escalation and dose-expansion study is evaluating the safety, tolerability, pharmacokinetics and antitumor activity of Cami as monotherapy or in combination with pembrolizumab. The primary completion date is July 2022.Cami is comprised of a CD25-targeting monoclonal antibody in-licensed from Genmab A/S (GMAB) linked to tesirine, a member of a class of antitumor antibiotics called pyrrolobenzodiazepines.

For further details see:

Early-stage study commences on ADC antibody-drug conjugate in solid tumors